SCHEMBL1970583

SCHEMBL1970583

Cc1cc([C@@H]2CN(C(=O)OC(C)(C)C)CC[C@H]2NC(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 5/20 0.44
STS P08842 2/20 0.41
CXCR3 P49682 2/20 0.41
MCL1 Q07820 1/20 0.40
UBE2M P61081 2/20 0.40
DCUN1D1 Q96GG9 2/20 0.40
RHOC P08134 1/20 0.40
RHOA P61586 1/20 0.40
EPHX2 P34913 2/20 0.40
RORC P51449 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TACR2 P21452 2/20 0.39
TACR3 P29371 1/20 0.39
USP30 Q70CQ3 1/20 0.39
PDE4B Q07343 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30693143 1.00 TACR1 (0.44) TACR1STSCXCR3MCL1UBE2M
SCHEMBL1969849 0.90 TACR1 (0.49) TACR1STSCXCR3UBE2MDCUN1D1
SCHEMBL30693214 0.90 TACR1 (0.49) TACR1STSCXCR3UBE2MDCUN1D1
SCHEMBL15397478 0.89 DCUN1D1 (0.44) TACR1CXCR3UBE2MDCUN1D1RHOC
SCHEMBL1973928 0.89 TACR1 (0.49) TACR1STSCXCR3UBE2MDCUN1D1
SCHEMBL1968682 0.89 TACR1 (0.51) TACR1STSCXCR3EPHX2RORC
SCHEMBL30693172 0.89 TACR1 (0.51) TACR1STSCXCR3EPHX2RORC
SCHEMBL13801293 0.88 TACR1 (0.46) TACR1STSMCL1TACR2TACR3
SCHEMBL13814703 0.88 TACR1 (0.46) TACR1STSMCL1TACR2TACR3
SCHEMBL1969544 0.87 TACR1 (0.49) TACR1STSCXCR3UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B TACR1 13/4885STS 2213/4885CXCR3 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.